MLA 0.00% 8.5¢ medical australia limited

Ann: APPENDIX 4E AND PRELIMINARY FINAL REPORT, page-3

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 798 Posts.
    lightbulb Created with Sketch. 10
    $1.6m revenue from the OEM business - under  the approx $2m @groberts estimate last year. Margins reasonable (but not specified) on this, so can assume a reduction in cashflow going into the next FY (and mrsb, I agree 35% sounds plausible). Given the business has nearly doubled its cash reserves over that period of time to $1.55m, I don't foresee this as an issue to overall cashflow going into the next FY assuming no improvements to either the Clements or TUTA businesses  - of which I personally believe there will be.

    I think it's quite possible this profitability is recouped over the coming 12mths on the groundwork laid by the Ardo launch by the Clements division. If it is an issue, I don't see why ICU would be making an offer. They've had exclusive access to the books and are offering ($10m net of cash) at a level that is beneficial to them on a company that has been trading at a low level for some time.... Predatory is the word.

    Interesting the final paragraph outlining a $112k payment made to Michael Jones's Wife (Rachel) for Ardo Clinical services... positive family benefits there...

    Nothing earth-shattering, I'm still of the believe that the ICU offer is too low, and would rather see the company continue as a going concern. Seems like management are looking to land a cushy role in the new enterprise, rather than do what's best for shareholders, but I might well be on my own with this view.

    all IMO, DYOR etc...
 
watchlist Created with Sketch. Add MLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.